Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Adicet Bio, Inc. (TORC) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 4 Galimi Francesco (SVP & Chief Medical Officer) has filed a Form 4 on Adicet Bio, Inc.
Txns: Paid exercise price by delivering 8,093 shares @ $1.37, valued at $11.1k
10/03/2023 4 Healey Don (Chief Technology Officer) has filed a Form 4 on Adicet Bio, Inc.
Txns: Paid exercise price by delivering 9,069 shares @ $1.37, valued at $12.4k
10/03/2023 4 Harvey Brian Nicholas (CFO) has filed a Form 4 on Adicet Bio, Inc.
Txns: Paid exercise price by delivering 7,096 shares @ $1.37, valued at $9.7k
10/02/2023 4 Schor Chen (President & CEO) has filed a Form 4 on Adicet Bio, Inc.
Txns: Sold 5,500 shares @ $1.42, valued at $7.8k
Bought 5,500 shares @ $1.42, valued at $7.8k
Sold 5,500 shares @ $1.3601, valued at $7.5k
Bought 5,500 shares @ $1.3345, valued at $7.3k
Paid exercise price by delivering 23,208 shares @ $1.37, valued at $31.8k
09/29/2023 144 Form 144 - Report of proposed sale of securities:
08/16/2023 4 Schor Chen (President & CEO) has filed a Form 4 on Adicet Bio, Inc.
Txns: Disposed/sold 36,857 options to buy @ $0
Granted 36,857 options to buy @ $0
Disposed/sold 872,111 options to buy @ $16.11, valued at $14M
Granted 872,111 options to buy @ $0
Disposed/sold 240,000 options to buy @ $13.27, valued at $3.2M
Granted 240,000 options to buy @ $0
Disposed/sold 421,600 options to buy @ $16.82, valued at $7.1M
Granted 421,600 options to buy @ $0
Disposed/sold 295,000 options to buy @ $15.52, valued at $4.6M
Granted 295,000 options to buy @ $0
Disposed/sold 384,900 options to buy @ $9.05, valued at $3.5M
08/16/2023 4 Galimi Francesco (SVP & Chief Medical Officer) has filed a Form 4 on Adicet Bio, Inc.
Txns: Disposed/sold 113,652 options to buy @ $5.97, valued at $678.5k
Granted 113,652 options to buy @ $0
Disposed/sold 77,269 options to buy @ $16.11, valued at $1.2M
Granted 77,269 options to buy @ $0
Disposed/sold 73,964 options to buy @ $13.27, valued at $981.5k
Granted 73,964 options to buy @ $0
Disposed/sold 26,625 options to buy @ $16.82, valued at $447.8k
Granted 26,625 options to buy @ $0
Disposed/sold 125,000 options to buy @ $15.52, valued at $1.9M
Granted 125,000 options to buy @ $0
Disposed/sold 117,200 options to buy @ $9.05, valued at $1.1M
08/16/2023 4 Aftab Blake (Chief Scientific Officer) has filed a Form 4 on Adicet Bio, Inc.
Txns: Disposed/sold 50,000 options to buy @ $15.93, valued at $796.5k
Granted 50,000 options to buy @ $0
Disposed/sold 56,612 options to buy @ $7.38, valued at $417.8k
Granted 56,612 options to buy @ $0
Disposed/sold 125,000 options to buy @ $15.52, valued at $1.9M
Granted 125,000 options to buy @ $0
Disposed/sold 60,000 options to buy @ $12.18, valued at $730.8k
Granted 60,000 options to buy @ $0
Disposed/sold 117,200 options to buy @ $9.05, valued at $1.1M
Granted 117,200 options to buy @ $0
08/16/2023 4 Harvey Brian Nicholas (CFO) has filed a Form 4 on Adicet Bio, Inc.
Txns: Disposed/sold 90,000 options to buy @ $13.27, valued at $1.2M
Granted 90,000 options to buy @ $0
Disposed/sold 28,200 options to buy @ $16.82, valued at $474.3k
Granted 28,200 options to buy @ $0
Disposed/sold 125,000 options to buy @ $15.52, valued at $1.9M
Granted 125,000 options to buy @ $0
Disposed/sold 117,200 options to buy @ $9.05, valued at $1.1M
Granted 117,200 options to buy @ $0
Granted 176,308 options to buy @ $2.14, valued at $377.3k
08/16/2023 4 Healey Don (Chief Technology Officer) has filed a Form 4 on Adicet Bio, Inc.
Txns: Disposed/sold 70,000 options to buy @ $13.27, valued at $928.9k
Granted 70,000 options to buy @ $0
Disposed/sold 30,400 options to buy @ $16.82, valued at $511.3k
Granted 30,400 options to buy @ $0
Disposed/sold 125,000 options to buy @ $15.52, valued at $1.9M
Granted 125,000 options to buy @ $0
Disposed/sold 117,200 options to buy @ $9.05, valued at $1.1M
Granted 117,200 options to buy @ $0
Granted 149,944 options to buy @ $2.14, valued at $320.9k
08/16/2023 4 GORDON CARL L (10% Owner) has filed a Form 4 on Adicet Bio, Inc.
Txns: Disposed/sold 30,000 options to buy @ $16.11, valued at $483.3k
Granted 30,000 options to buy @ $0
Disposed/sold 18,500 options to buy @ $15.93, valued at $294.7k
Granted 18,500 options to buy @ $0
Disposed/sold 18,500 options to buy @ $11.49, valued at $212.6k
Disposed/sold 26,400 options to buy @ $5.195, valued at $137.1k
Granted 26,400 options to buy @ $0
08/16/2023 4 Sanna Bastiano (Director) has filed a Form 4 on Adicet Bio, Inc.
Txns: Disposed/sold 28,828 options to buy @ $12, valued at $345.9k
Granted 28,828 options to buy @ $0
Disposed/sold 18,500 options to buy @ $15.93, valued at $294.7k
Granted 18,500 options to buy @ $0
Disposed/sold 1,172 options to buy @ $15.93, valued at $18.7k
Granted 1,172 options to buy @ $0
Disposed/sold 18,500 options to buy @ $11.49, valued at $212.6k
Disposed/sold 26,400 options to buy @ $5.195, valued at $137.1k
Granted 26,400 options to buy @ $0
08/16/2023 4 Sinclair Andrew (Director) has filed a Form 4 on Adicet Bio, Inc.
Txns: Disposed/sold 28,828 options to buy @ $15.75, valued at $454k
Granted 28,828 options to buy @ $0
Disposed/sold 18,500 options to buy @ $15.93, valued at $294.7k
Granted 18,500 options to buy @ $0
Disposed/sold 8,172 options to buy @ $15.93, valued at $130.2k
Granted 8,172 options to buy @ $0
Disposed/sold 18,500 options to buy @ $11.49, valued at $212.6k
Disposed/sold 26,400 options to buy @ $5.195, valued at $137.1k
Granted 26,400 options to buy @ $0
08/16/2023 4 Kauffman Michael (Director) has filed a Form 4 on Adicet Bio, Inc.
Txns: Disposed/sold 37,000 options to buy @ $9.39, valued at $347.4k
Granted 37,000 options to buy @ $0
Disposed/sold 18,500 options to buy @ $11.49, valued at $212.6k
Granted 18,500 options to buy @ $0
Disposed/sold 26,400 options to buy @ $5.195, valued at $137.1k
Granted 26,400 options to buy @ $0
08/16/2023 4 DUBIN STEVE (Director) has filed a Form 4 on Adicet Bio, Inc.
Txns: Disposed/sold 30,000 options to buy @ $16.11, valued at $483.3k
Granted 30,000 options to buy @ $0
Disposed/sold 18,500 options to buy @ $15.93, valued at $294.7k
Granted 18,500 options to buy @ $0
Disposed/sold 18,500 options to buy @ $11.49, valued at $212.6k
Disposed/sold 26,400 options to buy @ $5.195, valued at $137.1k
Granted 26,400 options to buy @ $0
08/16/2023 4 Jakobovits Aya (Director) has filed a Form 4 on Adicet Bio, Inc.
Txns: Disposed/sold 30,000 options to buy @ $16.11, valued at $483.3k
Granted 30,000 options to buy @ $0
Disposed/sold 18,500 options to buy @ $15.93, valued at $294.7k
Granted 18,500 options to buy @ $0
Disposed/sold 18,500 options to buy @ $11.49, valued at $212.6k
Disposed/sold 26,400 options to buy @ $5.195, valued at $137.1k
Granted 26,400 options to buy @ $0
08/16/2023 4 Chodakewitz Jeffrey (Director) has filed a Form 4 on Adicet Bio, Inc.
Txns: Disposed/sold 30,000 options to buy @ $16.11, valued at $483.3k
Granted 30,000 options to buy @ $0
Disposed/sold 18,500 options to buy @ $15.93, valued at $294.7k
Granted 18,500 options to buy @ $0
Disposed/sold 18,500 options to buy @ $11.49, valued at $212.6k
Disposed/sold 26,400 options to buy @ $5.195, valued at $137.1k
Granted 26,400 options to buy @ $0
08/16/2023 4 Peng Katie (Director) has filed a Form 4 on Adicet Bio, Inc.
Txns: Disposed/sold 70,200 options to buy @ $3.38, valued at $237.3k
Granted 70,200 options to buy @ $0
08/09/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates Announced encouraging safety and efficacy data in ongoing Phase 1study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma On track to report a clinical update for ADI-001 in second half of 2024 Plan to file Investigational New Drug Application for ADI-925 in H2 2023 and ADI-270 in H1 2024 Strong balance sheet with $205.5 million in cash and cash equivalents as of June 30, 2023 REDWOOD CITY, Calif. & BOSTON – August 9, 2023 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2023. &#x..."
07/11/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/11/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Adicet Announces Appointment of Katie Peng to the Board of Directors REDWOOD CITY, Calif. & BOSTON – July 11, 2023 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the appointment of Katie Peng to its Board of Directors. “We are delighted to welcome Katie to our Board of Directors,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “Her proven success as a commercial leader in both the U.S. and globally will be particularly valuable to Adicet as we advance ADI-001 and our pipeline of allogeneic gamma delta T cell therapy candidates in hematologic and solid tumors.” “I am pleased to join the Adicet Board at this exciting time for th..."
06/30/2023 4 DUBIN STEVE (Director) has filed a Form 4 on Adicet Bio, Inc.
Txns: Bought 5,000 shares @ $2.3999, valued at $12k
06/29/2023 4 GORDON CARL L (10% Owner) has filed a Form 4 on Adicet Bio, Inc.
Txns: Bought 125,000 shares @ $2.09, valued at $261.3k
Bought 250,000 shares @ $2.09, valued at $522.5k
Bought 442,000 shares @ $2.09, valued at $923.8k
Bought 58,000 shares @ $2.09, valued at $121.2k
06/29/2023 4 ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Adicet Bio, Inc.
Txns: Bought 125,000 shares @ $2.09, valued at $261.3k
Bought 250,000 shares @ $2.09, valued at $522.5k
Bought 442,000 shares @ $2.09, valued at $923.8k
Bought 58,000 shares @ $2.09, valued at $121.2k
06/29/2023 SC 13D/A ORBIMED ADVISORS LLC reports a 15.5% stake in Adicet Bio, Inc.
06/05/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "SIXTH AMENDMENTTO"
06/02/2023 4 Chodakewitz Jeffrey (Director) has filed a Form 4 on Adicet Bio, Inc.
Txns: Granted 5,900 shares @ $0
Granted 26,400 options to buy @ $5.195, valued at $137.1k
06/02/2023 4 Sanna Bastiano (Director) has filed a Form 4 on Adicet Bio, Inc.
Txns: Granted 5,900 shares @ $0
Granted 26,400 options to buy @ $5.195, valued at $137.1k
06/02/2023 4 Kauffman Michael (Director) has filed a Form 4 on Adicet Bio, Inc.
Txns: Granted 5,900 shares @ $0
Granted 26,400 options to buy @ $5.195, valued at $137.1k
06/02/2023 4 Jakobovits Aya (Director) has filed a Form 4 on Adicet Bio, Inc.
Txns: Granted 5,900 shares @ $0
Granted 26,400 options to buy @ $5.195, valued at $137.1k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy